HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lauder Investing In Americas Turnaround While Asia/Pacific Continues To Soar

Executive Summary

Prestige skin care continues to win big with young Chinese consumers, and makeup demand is picking up, according to Lauder leadership. Overall, the firm’s Asia/Pacific sales climbed 17%, reported, to $1.02bn, helping to offset continued declines in the Americas.

You may also be interested in...



Estee Lauder Companies Pumps Digital, Diversity With New Executive Appointments

J&J’s US beauty president Michelle Freyre will take over ELC’s Clinique business in July, succeeding Jane Lauder, who has been appointed to a new role at the company focused on driving its digital evolution.

Lauder Defies Specter Of China, Travel Retail Slowdowns, Raises FY 2020 Sales Targets

Lauder is responding to shifting trends with greater agility than ever while leveraging enhanced data analytics and consumer insight to innovate ahead of the curve, leadership says. Following 11% constant-currency growth in the fiscal 2020 first quarter, the firm is forecasting 8% to 9% net sales gains for the full year.

Estee Lauder Says Expected Q3 China Slowdown Didn’t Happen; More Financial News In Brief

Lauder again hikes its full-year net sales guidance after beating expectations with 11% reported growth in the fiscal 2019 third quarter. Coty reports on its turnaround progress, and Revlon points to optimistic improvements that drove Q1 constant-currency net revenue growth of 2.3%.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel